Abstract Background: Trastuzumab deruxtecan (T-DXd) was initially approved (Aug 2022) for treatment (trt) of HER2-low (IHC 1+ or IHC 2+/ISH-) unresectable or metastatic breast cancer (mBC) who have received a prior chemotherapy (CT) in the mBC setting. At approval, physicians in the US faced barriers in identifying patients (pts) with HER2-low for appropriate management. Florida Cancer Specialists .05) and decrease in chemotherapy use were observed between cohorts; T-DXd rates were slightly higher among pts in the notification program (Table). In sensitivity analysis, 1in 4 eligible pts utilized T-DXd in the intervention month/Oct 2022 whereas 3 in 7 utilized T-DXd in the following month/Nov 2022. There was a trend for improvement in population-level rwPFS from Cohort 1 to 2 (Table). All surveyed physicians (n=20) were very (35%) or somewhat familiar (65%) with current clinical guidelines for treating HER2-low mBC. A majority reported these types of notification programs as “very helpful” (65%) but recommended embedding such alerts into pt charts (vs emails) and tailoring to specifically target trt-eligible pts. Conclusions: QI such as AI-enabled notification program can increase awareness of trt guidelines and new indications. Real-world data metrics to assess impact of QI must be benchmarked for continuous enhancements of interventions design, maximize pt outreach, and ultimately improve pt-level health outcomes. No causal association can be inferred between trt patterns and intervention due to limited pre-intervention period and expected natural uptake of a new trt post-approval. Citation Format: S. Mehta, A. Meo, A. Warner, A. Hernandez, A. Alajrash, P. Kothiya, L. Gordan, M. Hussein. Physicians’ Perception 2025 Dec 9-12; San Antonio, TX. Philadelphia (PA): AACR; Clin Cancer Res 2026;32(4 Suppl):Abstract nr PS1-09-23.
Mehta et al. (Tue,) studied this question.